Faculty

More documents

Recommendations

Info

Antoine LAFONT Student at Necker medical school, Paris, PhD thesis (bioresorbable stents in vivo) Univ. Montpellier post-doctoral fellowship at the Cleveland Clinic Foundation 1989-1991 Professor of medicine, University PARIS V, Head of the dept of interventional cardiology, HEGP Adjunct staff, biomedical engineering Dept, Cleveland Clinic Foundation 1991-2006 Research fields arterial remodeling after injury Summary of research activity -role of constrictive remodelling on the occurrence of restenosis (Circ Res 1995). -Back in Paris, creation of a university research unit (2505) ( arterial remodelling) in 1998 -In 2000, creation of the EMI.U0016 on arterial development. -In 2003, startup (Arterial Remodeling Technology) -In 2004, potential beneficial properties of gingival fibroblasts on arterial repair in expansive remodeling, by inhibiting the activity of MMP9, and overexpressing TIMP2 and TGF beta in contact with smooth muscle cells. - In 2007, creation of U 849 : arterial repair(therapeutic options in interventional cardiology). Principal scientific and administrative responsibilities Head of EMI-U 0016 until 2006 Head of U 849 from 2007 CSS 4 (INSERM) until 2003 Supervision of DEA(6) & thesis (6) Member of the commission du 3 e cycle, Université Paris V Member of the research committee of HEGP Review in the peer review process of journals: ATVB, Heart, Journal of the American College of Cardiology, American Journal of Cardiology, Cardiovascular Research, Biomaterials, Circulation. Industrial ccoperations and valorisation Nine patents involving bioresorbable stent, decorin and prevention of intrastent restenosis identification and therapeutic use of side population cells, use of gingival fibroblasts in the treatment of pathologic remodeling Creation of 2 start-up :Arterial Remodeling Technologies (2003);ScarCell (2007) Scientific information 70 invited lectures (2000-2007) International activities -Coordinator of 2 international, multicentric, randomised, double blind study (FROST, PRACTICE) -Chairman, working group on interventional cardiology, European Society of Cardiology 2003-2006 -Past Chairman of the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology -Director, International Affairs, Medical School PARIS-DESCARTES Teaching activities Faculté de médecine Paris: cardiology, physiology
Philippe LECHAT Professor Philippe LECHAThas joined the French Health Products Safety Agency as Head of the Medicinal Products and Biologics Evaluation Department in July 2007 and has been appointed as CHMP member since October 2007. Philippe Lechat is a 55 years old physician cardiologist. He obtained his Ph D in Pharmacology from the Pitié-Salpêtrière <strong>Faculty</strong> of Medicine, Paris and is Pharmacology Professor. His professional involvement led him to become Head of the Pharmacology Department at the Pitié Salpêtrière Hospital. He was also very much concerned with experimental and clinical research. Philippe Lechat was thus Responsible for the Clinical Research Unit and Chairman of the Committee for the Protection of Patients. He participated in the carrying out and follow up of several multicentric and international (especially in the cardio-vascular area) clinical studies. Besides, he brought his contribution to the French Health Products Safety Agency and became member of the Marketing Authorization Committee and Chairman of the Thrombosis Working Party. In addition, Philippe Lechat participated in the activities of various learned societies. He was thus much involved in the creation and development of the French Society of Pharmacology. His principal areas of expertise are cardiology, cardio-vascular pharmacology, pharmaco genetics and clinical pharmacology. His is also the author of more than 150 international scientific publications and has participated in several scientific reviewing and editorial committees. ____________________________________________________________________________ Raymond John LIPICKY, MD He is the Director of LIPICKY, LLC (a consulting company) having retired (March 2002) after 21 years of service) from the U.S Food and Drug Administration (FDA) where he held the position of Director, Division of Cardio-Renal Drug Products, Office of Drug Evaluation I, Center for Drug Evaluation and Research. Previously, he was on the faculty of University of Cincinnati, College of Medicine (for 14 years) where he held the positions of Professor of Pharmacology and Professor of Medicine and Director, Division of Clinical Pharmacology at the time he joined FDA. He is a graduate of the University of Cincinnati College of Medicine, trained in Internal Medicine and Cardiology. He currently also has an appointment as Visiting Scientist at the Marine Biological Laboratory (Woods Hole, MA) where, for about 30 years, he had a summer laboratory pursuing an interest in drug effects on electrically-excitable membranes. ____________________________________________________________________________ Jacobus LUBSEN Jacobus Lubsen's (1942) main interests are the translation of clinical problems into appropriate clinical trial design and/or their decision analytic modelling. He studied engineering in Delft, medicine in Rotterdam and epidemiology at the Harvard School of Public Health in Boston. After completing a cum laude thesis on acute chest pain syndromes in general practice, he started in 1978 the Clinical Epidemiology group at the Department of Cardiology (Thoraxcentre) of the Erasmus University Rotterdam. In 1985 he was appointed professor of medicine at Erasmus and in 1987 Chairman of the Centre for Clinical Decision Analysis. From 1990 - 2006 he was scientific director of SOCAR Research SA, a Swiss-based cardiovascular clinical research organisation. At SOCAR, he was 'responsible biostatistician' of the ACTION study, the first-ever clinical outcome trial in patients with stable symptomatic coronary disease. As a part-time faculty member at the Erasmus University, he contributes regularly to teaching in clinical trials and decision analysis, and lectures frequently at international meetings. He is a past member of the Dutch Health Council.
Page 1 and 2: Faculty
Page 3 and 4: GUSTAFSSON Finn Department of Cardi
Page 5 and 6: STAGNITTO Maria Director Office of
Page 7 and 8: Jeffrey S. BORER,M.D Biographical S
Page 9 and 10: Gad COTTER, MD, FACC EDUCATION/TRAI
Page 11 and 12: Nancy L. GELLER She has been the Di
Page 13 and 14: Finn GUSTAFSSON, M.D., Ph.D. Educat
Page 15: Abraham M. KARKOWSKY, M.D., Ph.D. E
Page 19 and 20: Bertram PITT M.D. Education 1945-49
Page 21 and 22: James H. REVKIN, MD, FACC, FACP Sen
Page 23 and 24: Charles L. SHEAR, Dr.P.H., F.A.H.A.
Page 25 and 26: Philippe Gabriel STEG, MD, FESC, FA
Page 27 and 28: Hans WEDEL I have been professor in

Faculty

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?